Crypto7o 🔥🚨💎
@Crypto7o
🏴🇵🇹 No One Ever Went Broke By Taking Profit.
Was dir gefallen könnte
$GNPX has a habit of moving exactly when people get bored. We’re in that quiet window right now, but if you look at the calendar, the board is basically set for a massive few months. 📊 In case you missed the recent updates, here is what we are actually waiting on: First is the…
$GNPX ON FIRE RIGHT NOW! 🔥💥🚀 JUST BROKE OUT HARD from rounded bottom – OBV exploding, - MFI at 74 screaming inflow, - ADX >27 confirming the TREND IS YOUR FRIEND! +8% today on volume surge! 📈 FRESH CATALYSTS DROPPING: Jan 2026 positive preclinical data for GPX-002…
@elonmusk At what market cap does something officially become “interesting” again? Asking for a very patient biotech stock called $GNPX 👀
Amazing news! They are off the non compliant companies list as well. #gnpx #StocksToBuy #StockMarket #Biotech
$GNPX Exciting update The Nasdaq compliance alert has vanished nasdaq.com/market-activit… Genprex appears to be back in good standing after meeting the stockholders’ equity requirement via recent capital raises. No delisting risks in sight as of Jan 2026. with positive preclinical…
nasdaq.com
GNPX
GNPX
Rep. Tim Moore of North Carolina’s 14th District has filed a new periodic transaction report showing active trading across multiple publicly traded stocks. His latest disclosure includes several purchases and sales spanning retail, biotech, automotive, manufacturing,…
$GNPX One stock that caught my attention last week was Genprex. The Rep. Tim Moore disclosed a purchase of shares Bought on 10/29/2025 ($15,001-$50,000), something unusual for a small bio name but with a good pipeline. This is a beaten down name with a HIGH short interest and a…
🔥 $GNPX — Capitulation Done? Reversal Loading. After a brutal drop from $55 to $3.90, $GNPX is finally showing signs of life — RSI rebounding from oversold, MFI at rock-bottom (2.5!), and OBV flattening = sellers exhausted. ⚡ Holding above $4.00 could confirm a near-term…
$GNPX skyrocketed 265% amid heavy speculation and high trading volume! While overbought with RSI at 96, the buzz around gene therapy breakthroughs is real. Watch for potential corrections, but fundamentals point to long-term growth. #StockMarket #GNPX
Spotted $GNPX on BioPharma Watch upcoming catalysts list 😏 Reqorsa® Phase 2 readout 2H 2025. Non-viral gene therapy combo in hard-to-treat lung cancer. Phase 1 efficacy already published & promising. Float is tiny. One strong data drop and this runner goes parabolic. Watching…
$GNPX is SLEEPING GIANT mode right now 😴💤 Low float. Tiny mcap. Patents locked through 2037+. REQORSA Phase 1 already dropping prolonged PFS bombs. Phase 2 interims H1 2026 (Tagrisso & Tecentriq combos) about to wake the street up. When this data hits and the squeeze…
$GNPX I’ll say it straight… this chart rarely sits still this long. Low float. Tight range. Volume waking up. Stocks like this don’t walk when they move… they jump. If it clears 3.55–3.70 with real volume, that’s where things get loud. I’ve seen this exact setup before it…
If you trade charts, pull up $GNPX for 10 seconds. Tell me that’s not one of the cleanest coil-and-volume setups you’ve seen this month. Float is tiny. Pressure is building. These usually break harder than people expect.
$PLBY $VG $SMX $BULL $GNPX If you trade low-float setups… Look. At. This. Chart. 👇 $GNPX is doing the exact same slow build we saw before the last runners took off. Not hype. Not a pump. Just the pattern. 🌀🔥
$GNPX finally showing a change in behaviour. Lows got swept, buyers stepped in, MACD turning, RSI recovering, volume building under a thin zone above 3.00. Break 3.03 and there’s room.
$GNPX just dropped one of the cleanest early-stage oncology readouts I’ve seen in a long time… and barely anyone is talking about it. • No dose-limiting toxicities • Durable partial responses • Strong safety profile • Gene-therapy angle most people are sleeping on…
Gene therapy in NSCLC isn’t exactly crowded. If $GNPX keeps showing this kind of safety + durability combo, it won’t stay under the radar for long. @bradloncar @AndyBiotech what’s your read on early-stage GT in lung cancer right now?
$GNPX just quietly dropped one of the cleaner early-stage oncology updates I’ve seen in a while. Most people aren’t paying attention yet… but the data is right there. – No dose-limiting toxicities – Durable partial responses – Clean safety readout – Gene therapy approach that’s…
Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer: ow.ly/8Lkx50XwPnx #genetherapy #lungcancer $GNPX
Huge step for $GNPX today. Peer-reviewed Phase 1 data showing no DLTs, a confirmed RP2D, and patients with long durable responses (one still holding a PR at 32+ months). Solid science behind the scenes. Exactly the kind of progress that gets overlooked during the noise. 🚀
Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer: ow.ly/8Lkx50XwPnx #genetherapy #lungcancer $GNPX
Pre-market radar locked in. ⚡️ If $GNPX decides to wake up today, it won’t tiptoe… it’ll sprint. Tiny float, fresh 10-Q, Congress money sniffing around, and a chart everyone hates until it doesn’t. Feels like one of those names that can go from “ignored” to “everyone’s FOMO…
![dogecoin's profile picture. Dogecoin is an open source peer-to-peer cryptocurrency, favored by shibas worldwide. Elon Musk thinks we're pretty cool. [RTs are not endorsements]](https://pbs.twimg.com/profile_images/378800000857919980/lHqPIZza.png)
United States Trends
- 1. #WWENXT N/A
- 2. Harden N/A
- 3. Cavs N/A
- 4. #ProBowlGames N/A
- 5. Joe Hendry N/A
- 6. Thune N/A
- 7. Garland N/A
- 8. SAVE Act N/A
- 9. #Fallout N/A
- 10. #SummerHouse N/A
- 11. #HighPotential N/A
- 12. Chris Beard N/A
- 13. Skinner N/A
- 14. Isaiah Collier N/A
- 15. Micah Parsons N/A
- 16. Clippers N/A
- 17. Kaitlan N/A
- 18. Elijah N/A
- 19. Zaria N/A
- 20. Nate Ament N/A
Something went wrong.
Something went wrong.